Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Personal Protective Equipment01:20

Personal Protective Equipment

Personal protective equipment (PPE) is unique clothing or equipment worn by an employee to minimize or prevent exposure to infectious agents. PPE creates a barrier between the employee and the infectious materials. PPE must be readily available in the patient care area. PPE includes gloves, gowns and aprons, masks and respirators, goggles, face shields, shoes, and headcovers:
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines.

Circulation. Heart failure·2014
Same author

Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions.

International journal of cardiology·2014
Same author

Saxagliptin, alogliptin, and cardiovascular outcomes.

The New England journal of medicine·2014
Same author

Quality of care for patients with acute coronary syndromes as a function of hospital revascularization capability: Insights from get with the guidelines-CAD.

Clinical cardiology·2014
Same author

Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study.

European journal of preventive cardiology·2014
Same author

Obstructive sleep apnea and diurnal nondipping hemodynamic indices in patients at increased cardiovascular risk.

Journal of hypertension·2013
Same journal

Sex differences in reverse remodeling after transcatheter aortic valve replacement in low-flow aortic stenosis.

The Journal of invasive cardiology·2026
Same journal

Coronary computed tomography angiography to guide percutaneous coronary intervention: proceedings from the 1st CCTA-guided PCI summit in the United States.

The Journal of invasive cardiology·2026
Same journal

When not to pull: radial srtery spasm, catheter entrapment, and the value of waiting.

The Journal of invasive cardiology·2026
Same journal

Severe coronary vasospasm mimicking STEMI after drug-coated balloon angioplasty.

The Journal of invasive cardiology·2026
Same journal

Imaging insights into endothelial response: cardiac computed tomography assessment of WATCHMAN FLX and FLX Pro.

The Journal of invasive cardiology·2026
Same journal

Differential effect of chronic kidney disease on right-sided extravalvular damage in low-flow, low-gradient aortic stenosis.

The Journal of invasive cardiology·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
11:49

Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model

Published on: September 9, 2011

Emboli protection devices.

Deepak L Bhatt1

  • 1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA. bhattd@ccf.org

The Journal of Invasive Cardiology
|April 12, 2013
PubMed
Summary
This summary is machine-generated.

Preventing emboli and microvascular obstruction is crucial for acute atherosclerotic vascular disease. New emboli protection devices are needed to improve procedural success while minimizing embolization during use.

More Related Videos

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

Related Experiment Videos

Last Updated: May 12, 2026

Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
11:49

Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model

Published on: September 9, 2011

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

Area of Science:

  • Vascular Surgery
  • Cardiology
  • Biomedical Engineering

Background:

  • Acute atherosclerotic vascular disease management requires preventing embolization and microvascular obstruction.
  • Current treatment strategies necessitate effective emboli protection devices.

Purpose of the Study:

  • To highlight the need for emboli protection devices.
  • To emphasize the importance of procedural efficacy and minimal embolization provocation.

Main Methods:

  • Literature review on current emboli protection devices.
  • Analysis of procedural outcomes in atherosclerotic vascular disease.

Main Results:

  • Embolization and microvascular obstruction are significant complications.
  • Existing devices may provoke embolization, impacting efficacy.

Conclusions:

  • Development of novel emboli protection devices is critical.
  • Future devices must balance procedural efficacy with reduced embolization provocation.